Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35212007 | 0.90 | MEN1 (0.32) | — | |
| SCHEMBL34466692 | 0.89 | — | — | |
| SCHEMBL34466694 | 0.89 | — | — | |
| SCHEMBL34467127 | 0.89 | — | — | |
| SCHEMBL35212284 | 0.89 | SUV39H2 (0.34) | CCR1 | |
| SCHEMBL35211741 | 0.89 | SUV39H2 (0.34) | CCR1 | |
| SCHEMBL34466554 | 0.89 | CFD (0.30) | — | |
| Hydrochloric Acid SCHEMBL34466899 | 0.88 | CFD (0.30) | — | |
| SCHEMBL34466256 | 0.85 | CCR1 (0.32) | CCR1 | |
| SCHEMBL35212023 | 0.85 | CFD (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109704-A1 | 5-MEMBERED HETEROARYL INDAZOLE CGAS INHIBITORS AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108509-A1 | 6-MEMBERED HETEROARYL INDAZOLE CGAS INHIBITORS AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2026-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109704-A1 | 5-MEMBERED HETEROARYL INDAZOLE CGAS INHIBITORS AND USES THEREOF | CGAS, GBA3, CYP11B2 | CCR1 1423/4885 |
| US-20260108509-A1 | 6-MEMBERED HETEROARYL INDAZOLE CGAS INHIBITORS AND USES THEREOF | CGAS, GBA3, GBA1 | CCR1 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.